Journal of obesity & metabolic syndrome · 2020
Current Long-Term Pharmacotherapies for the Management of Obesity.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Bo-Yeon, Kang Seon Mee, Kang Jee-Hyun, Kim Kyoung Kon, Kim Bomtaeck, Kim Seung Jun, Kim Yang-Hyun, Kim Jung-Hwan, Kim Jae Hyun, Nam Ga Eun, Park Ji Yeon, Son Jang Won, Shin Hye-Jung, Oh Tae Jung, Lee Hyug, Jeon Eon-Ju, Chung Sochung, Hong Yong Hee, Kim Chong Hwa, Committee of Clinical Practice Guidelines, Korean Society for the Study of Obesity (KSSO)
Аннотация
Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients with a body mass index ≥25 kg/m2. Long-term medications for obesity have traditionally fallen into two major categories: centrally acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, we provide an overview of the anti-obesity medications currently available for the long-term and individualized treatment of obesity.